# Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

> **NCT01069120** · PHASE3 · TERMINATED · sponsor: **Repros Therapeutics Inc.** · enrollment: 27 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** Proellex
- **DRUG:** Proellex

## Key facts

- **NCT ID:** NCT01069120
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Repros stopped study due to safety and FDA placed study on hold
- **Last updated:** 2014-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01069120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01069120, "Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01069120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*